Global Malaria Programme



The use of nonpharmaceutical forms of Artemisia



Global Malaria Programme



The use of nonpharmaceutical forms of *Artemisia*



The use of non-pharmaceutical forms of Artemisia

WHO/CDS/GMP/2019.14

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The use of non-pharmaceutical forms of *Artemisia*. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Table of contents

WHO position on the use of non-pharmaceutical forms of Artemisia	V
Introduction	1
The discovery of artemisinin	1
Artemisinin and its derivatives	2
Development of ACTs	3
Resistance	4
Surveillance of recommended treatment for uncomplicated malaria	5
Non-pharmaceutical use of Artemisia for malaria	6
A. annua	6
Other Artemisia species used in herbal remedies	8
Efficacy of non-pharmaceutical forms of Artemisia for malaria	9
References	14

OC

WHO POSITION ON THE USE OF NON-PHARMACEUTICAL FORMS OF ARTEMISIA

WHO does not support the promotion or use of *Artemisia* plant material in any form for the prevention or treatment of malaria.

This position is based on the following considerations:

• The content of the *Artemisia* herbal remedies given for malaria treatment and prevention varies substantially.

The content and quality of the *Artemisia* herbal remedies are affected by variations in the content of the plant material and the preparation method.

A range of factors can affect the content of *Artemisia*, including genetics, at what point in the season the harvesting takes place, temperature, nutrient availability, and from where on the plant the leaves are harvested. Processing, drying procedures, and storage conditions further influence the content of plant materials. It is not feasible to implement the required level of quality control for cultivation, harvest and post-harvest aspects of *Artemisia* in the context of home-grown or small-scale cultivation.

The preparation method will cause further variation. The content of *Artemisia* tea is highly influenced by factors such as the temperature of the water. Even given in tablet or capsule form, the content of these will differ from the original source material.

• Content in *Artemisia* herbal remedies is often insufficient to kill all malaria parasites in a patient's bloodstream and to prevent recrudescence.

To achieve high efficacy rates, sufficient levels of artemisinin need to be administrated and absorbed over seven days. The pharmacological properties of artemisinin mean that higher levels of artemisinin need to be administered on the last days of treatment than on the first days in order to achieve the same artemisinin blood levels. Too short treatments or too low blood levels of artemisinin will result in either failure to clear parasites from the blood or high levels of recrudescence. *Artemesia annua* contains varying levels of artemisinin. Herbal remedies prepared using *A. annua* with significant artemisinin content may improve symptoms, but are likely to result in high recrudescence rates. The available evidence does not support claims that the antimalarial activity of other plant constituents or synergism between artemisinin and other constituents will significantly increase the efficacy of non-pharmaceutical forms of *A. annua*.

Artemesia afra does not contain artemisinin or any other compound identified as having significant antimalarial activity in vitro.

• Widespread use of *A. annua* herbal remedies could hasten the development and spread of artemisinin resistance.

Artemisinin and artemisinin derivatives are the key compound in the artemisinin-based combination therapies (ACTs) used to treat millions suffering from malaria. The artemisinin derivative, artesunate, is used to save the lives of those suffering from severe malaria. Resistance causing the loss of the effectiveness of these drugs would be a disaster. In 2007, WHO Member States adopted World Health Assembly resolution WHA60.18 calling for a •

THE USE OF NON-PHARMACEUTICAL FORMS OF ARTEMISIA

progressive removal of oral artemisinin-based monotherapies from markets and deployment of ACTs instead. This decision was made to help protect artemisinin drugs from resistance. If consumption of *A. annua* becomes widespread, any potential weak antimalarial activity of other compounds in *A. annua* would not be sufficient to protect artemisinin from resistance. Resistance is more likely to develop and spread when a parasite population is exposed to sub-therapeutic levels of an antimalarial drug. The varying artemisinin content of *A. annua* herbal remedies means that widespread use of these remedies could lead to many people having such sub-therapeutic levels of artemisinin in their blood.

• Artemisinin in any form does not work well as prevention against malaria.

Artemisinin has a short elimination half-life, meaning that it only remains in the blood at therapeutic levels for a short time. Therefore, artemisinin is not recommended for use in malaria chemoprophylaxis in any form.

• Affordable and efficacious treatments for malaria are available.

WHO recommends ACTs for the treatment of uncomplicated *P. falciparum* malaria. Artemisinin partial resistance and resistance to some partner drugs do pose a challenge in parts of South-East Asia. However, there are still highly efficacious treatments available that can cure all strains of malaria. All those affected by malaria must have access to ACTs. Countries should strengthen their regulatory systems to protect patients from counterfeit and substandard treatments; this includes any products promoted for treatment of malaria without the necessary information in terms of their content, quality, safety and efficacy.

Herbal medicines have been a key source for the discovery of antimalarial medicines. It is possible that future antimalarial compounds will also be discovered through research on the herbal treatments used in the past. However, any research needs to respect the ethical principles for medical research involving human subjects and be approved by local ethical committees. The well-being of the individual research subject must take precedence over all other interests. Medical research involving human subjects must conform to generally accepted scientific principles and be based on thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory experimentation*.

预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 25010